Key points
- Amphotericin B comes in different formulations, and they are not interchangeable.
- Its main interaction risks are different from the azoles.
- The most important problems are usually kidney stress, low potassium, low magnesium, and additive toxicity with other medicines.
- These risks matter most with intravenous treatment.
- If you hear “amphotericin B”, it is important to know which formulation is being used.
What is amphotericin B?
Amphotericin B is an antifungal used mainly for serious fungal infections. In modern UK practice this often means liposomal amphotericin B, but conventional amphotericin B deoxycholate is also a recognised formulation.
Why amphotericin B interactions are different from azoles
Unlike azole antifungals, amphotericin B does not mainly cause medicine interactions through liver enzymes. Its most important interaction risks usually relate to kidney injury, low potassium, low magnesium, and infusion-related effects.
The interaction groups most likely to matter
Other medicines that can damage the kidneys
This is one of the most important groups. Combining amphotericin B with other nephrotoxic medicines can increase the risk of kidney injury.
Diuretics, steroids, and other medicines that lower potassium
Amphotericin B can lower potassium, and some other medicines can make this worse. This may increase the risk of weakness, cramps, or heart rhythm problems.
Digoxin and heart-rhythm-sensitive situations
Low potassium caused by amphotericin B can make digoxin-related toxicity more likely and may increase the importance of electrolyte monitoring.
Flucytosine
When combined with flucytosine, specialist monitoring may be needed because toxicity can increase.
Some cancer medicines and intensive hospital treatments
In hospital, additive toxicity with other intensive treatments may be particularly important, especially where kidneys and electrolytes are already under strain.
White blood cell transfusions
Acute lung reactions are a recognised specialist concern if amphotericin B is given during or soon after leukocyte transfusions.
Why the formulations matter
Amphotericin B formulations are not interchangeable. Conventional amphotericin B deoxycholate and liposomal amphotericin B have different dosing, different handling by the body, and different safety profiles. Using the wrong formulation in the wrong dose has caused serious and even fatal errors.
In general, liposomal amphotericin B is less nephrotoxic than conventional amphotericin B deoxycholate, but it still requires careful monitoring.
What patients should do in practice
- Ask which amphotericin B formulation is being used.
- Tell the clinical team about all medicines, especially kidney-risk medicines, diuretics, steroids, and digoxin.
- Expect blood tests to monitor kidney function, potassium, and magnesium during intravenous treatment.
- Report weakness, reduced urine output, worsening swelling, palpitations, or marked dizziness.
When to seek medical advice
Seek urgent medical help for severe breathlessness, fainting, major palpitations, or a rapid deterioration during treatment.
Important
This page is educational and does not list every possible interaction. Amphotericin B treatment is usually managed by specialist teams, especially when given intravenously.
References
Latest News posts
News archive